NASDAQ:CDNA - CareDx Stock Price, Forecast & News

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

CareDx Inc (NASDAQ:CDNA) released its quarterly earnings data on Thursday, October, 31st. The company reported $0.02 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.01 by $0.01. The company had revenue of $33.80 million for the quarter, compared to analysts' expectations of $33.14 million. CareDx had a negative net margin of 18.25% and a negative return on equity of 21.92%. The business's revenue for the quarter was up 59.4% compared to the same quarter last year. View CareDx's Earnings History.

CareDx is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for CareDx.

CareDx updated its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $127-127.3 million, compared to the consensus revenue estimate of $125.4 million.

5 equities research analysts have issued 1-year price objectives for CareDx's shares. Their forecasts range from $35.00 to $63.00. On average, they anticipate CareDx's stock price to reach $47.40 in the next year. This suggests a possible upside of 100.8% from the stock's current price. View Analyst Price Targets for CareDx.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CareDx.

Headlines about CDNA stock have trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. CareDx earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for CareDx.

CareDx saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 3,890,000 shares, an increase of 5.7% from the November 28th total of 3,680,000 shares. Based on an average daily volume of 768,400 shares, the short-interest ratio is currently 5.1 days. Currently, 9.5% of the company's stock are short sold. View CareDx's Current Options Chain.

Some companies that are related to CareDx include Natera (NTRA), InVitae (NVTA), Veracyte (VCYT), RadNet (RDNT), Castle Biosciences (CSTL), Personalis (PSNL), Centogene (CNTG), Fulgent Genetics (FLGT), Enzo Biochem (ENZ), DermTech (DMTK), Celcuity (CELC), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN) and Biocept (BIOC).

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include EXACT Sciences (EXAS), Aduro BioTech (ADRO), Alibaba Group (BABA), Advanced Micro Devices (AMD), Roku (ROKU), Tandem Diabetes Care (TNDM), Square (SQ), Micron Technology (MU), NVIDIA (NVDA) and AbbVie (ABBV).

CareDx's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (1.49%), Selz Capital LLC (0.19%), TIAA FSB (0.14%), Sanders Morris Harris LLC (0.10%) and Alpine Global Management LLC (0.03%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Michael Goldberg, Mitchell J Nelles, Neil Gagnon, Peter Maag, Sasha King and William A Hagstrom. View Institutional Ownership Trends for CareDx.

CDNA stock was sold by a variety of institutional investors in the last quarter, including TIAA FSB. Company insiders that have sold CareDx company stock in the last year include James P Yee, Michael Brian Bell, Michael Goldberg, Peter Maag, Sasha King and William A Hagstrom. View Insider Buying and Selling for CareDx.

CDNA stock was acquired by a variety of institutional investors in the last quarter, including Selz Capital LLC, Sanders Morris Harris LLC, Peregrine Capital Management LLC and Alpine Global Management LLC. View Insider Buying and Selling for CareDx.

Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CDNA stock can currently be purchased for approximately $23.61.

CareDx has a market capitalization of $1.00 billion and generates $76.57 million in revenue each year. The company earns $-46,760,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. CareDx employs 227 workers across the globe.View Additional Information About CareDx.

The official website for CareDx is http://www.caredxinc.com/.

CareDx's mailing address is 3260 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The company can be reached via phone at 415-287-2300 or via email at [email protected]